Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know

References

1. 1.↵
   1. Novak JC,
   2. Lovett-Racke AE,
   3. Racke MK

   . Monoclonal antibody therapies and neurologic disorders. Arch Neurol 2008;65:1162–65 doi:10.1001/archneur.65.9.1162 pmid:18779418

   CrossRefPubMed
2. 2.↵
   1. Yu YJ,
   2. Watts RJ

   . Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 2013;10:459–72 doi:10.1007/s13311-013-0187-4 pmid:23549647

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Keilholz U

   . CTLA-4: negative regulator of the immune response and a target for cancer therapy. J Immunother 2008;31:431–39 doi:10.1097/CJI.0b013e318174a4fe pmid:18463542

   CrossRefPubMed
4. 4.↵
   1. Cranmer LD,
   2. Hersh E

   . The role of CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007;25:613–31 doi:10.1080/07357900701522315 pmid:18027152

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Sanderson K,
   2. Scotland R,
   3. Lee P, et al

   . Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741–50 doi:10.1200/JCO.2005.01.128 pmid:15613700

   Abstract/FREE Full Text
6. 6.↵
   1. Boasberg P,
   2. Hamid O,
   3. O’Day S

   . Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol 2010;37:440–49 doi:10.1053/j.seminoncol.2010.09.004 pmid:21074058

   CrossRefPubMed
7. 7.↵
   1. Kaehler KC,
   2. Piel S,
   3. Livingstone E, et al

   . Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010;37:485–98 doi:10.1053/j.seminoncol.2010.09.003 pmid:21074064

   CrossRefPubMed
8. 8.↵
   1. Ribas A,
   2. Hauschild A,
   3. Kefford R, et al

   . Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008;26:(Suppl 15):LBA9011–11.1 doi:10.1200/jco.2008.26.15_suppl.lba9011

   CrossRef
9. 9.↵
   1. Usiskin SI,
   2. Bainbridge A,
   3. Miller RF, et al

   . Progressive multifocal leukoencephalopathy: serial high-b value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy. AJNR Am J Neuroradiol 2007;28:285–86 pmid:17296996

   PubMed
10. 10.↵
    1. Sato N,
    2. Sze G,
    3. Endo K

    . Hypophysitis: endocrinologic and dynamic MR findings. AJNR Am J Neuroradiol 1998;19:439–44 pmid:9541295

    PubMedWeb of Science
11. 11.↵
    1. Agarwala SS,
    2. Ribas A

    . Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 2010;33:557–69 doi:10.1097/CJI.0b013e3181dcd260 pmid:20551840

    CrossRefPubMed
12. 12.↵
    1. Caturegli P,
    2. Newschaffer C,
    3. Olivi A, et al

    . Autoimmune hypophysitis. Endocr Rev 2005;26:599–614 doi:10.1210/er.2004-0011 pmid:15634713

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Leporati P,
    2. Landek-Salgado MA,
    3. Lupi I, et al

    . IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab 2011;96:1971–80 doi:10.1210/jc.2010-2970 pmid:21593109

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Lutterotti A,
    2. Martin R

    . Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008;7:538–47 doi:10.1016/S1474-4422(08)70110-8 pmid:18485317

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Ciccia F,
    2. Rizzo A,
    3. Guggino G, et al

    . Clinical efficacy of α4 integrin block with natalizumab in ankylosing spondylitis. Ann Rheum Dis 2016;75:2053–54 doi:10.1136/annrheumdis-2016-209749 pmid:27553212

    FREE Full Text
16. 16.↵
    1. Clifford DB,
    2. De Luca A,
    3. Simpson DM, et al

    . NTZ-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438–46 doi:10.1016/S1474-4422(10)70028-4 pmid:20298967

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Carson KR,
    2. Evens AM,
    3. Richey EA, et al

    . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834–40 doi:10.1182/blood-2008-10-186999 pmid:19264918

    Abstract/FREE Full Text
18. 18.↵
    1. Yousry TA,
    2. Pelletier D,
    3. Cadavid D, et al

    . Magnetic resonance imaging pattern in NTZ-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012;72:779–87 doi:10.1002/ana.23676 pmid:23280794

    CrossRefPubMed
19. 19.↵
    1. Koralnik IJ

    . Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006;60:162–73 doi:10.1002/ana.20933 pmid:16862584

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Boster A,
    2. Hreha S,
    3. Berger JR, et al

    . Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol 2009;66:593–99 doi:10.1001/archneurol.2009.31 pmid:19433659

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Wattjes MP,
    2. Richert ND,
    3. Killestein J, et al

    . The chameleon of neuroinflammation: magnetic resonance imaging characteristics of NTZ-associated progressive multifocal leukoencephalopathy. Mult Scler 2013;19:1826–40 doi:10.1177/1352458513510224 pmid:24192217

    CrossRefPubMed
22. 22.↵
    1. Kastrup O,
    2. Maschke M,
    3. Diener HC, et al

    . Progressive multifocal leukoencephalopathy limited to the brain stem. Neuroradiology 2002;44:227–29 doi:10.1007/s00234-001-0714-6 pmid:11942377

    CrossRefPubMed
23. 23.↵
    1. Cordoliani S

    . MRI aspects of progressive multifocal leukoencephalopathy. J Neuroradiol 1995;22:172–79 pmid:7472533

    PubMed
24. 24.↵
    1. Langer-Gould A,
    2. Atlas SW,
    3. Green AJ, et al

    . Progressive multifocal leukoencephalopathy in a patient treated with NTZ. N Engl J Med 2005;353:375–81 doi:10.1056/NEJMoa051847 pmid:15947078

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Wattjes MP,
    2. Verhoeff L,
    3. Zentjens W, et al

    . Punctate lesion pattern suggestive of perivascular inflammation in acute NTZ-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML IRIS manifestation? J Neurol Neurosurg Psychiatry 2013;84:1176–77 doi:10.1136/jnnp-2013-304986 pmid:23695498

    FREE Full Text
26. 26.↵
    1. Bergui M,
    2. Bradac GB,
    3. Oguz KK, et al

    . Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. Neuroradiology 2004;46:22–25 doi:10.1007/s00234-003-1115-9 pmid:14593446

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Fine AJ,
    2. Sorbello A,
    3. Kortepeter C, et al

    . Central nervous system herpes simplex and varicella zoster virus infections in NTZ-treated patients. Clin Infect Dis 2013;57:849–52 doi:10.1093/cid/cit376 pmid:23728144

    CrossRefPubMed
28. 28.↵
    1. Kwiatkowski A,
    2. Gallois J,
    3. Bilbault N, et al

    . Herpes encephalitis during NTZ treatment in multiple sclerosis. Mult Scler 2012;18:909–11 doi:10.1177/1352458511428082 pmid:22048950

    CrossRefPubMed
29. 29.↵
    1. Eisele P,
    2. Szabo K,
    3. Griebe M, et al

    . Reduced diffusion in a subset of acute MS lesions: a serial multiparametric MRI study. AJNR Am J Neuroradiol 2012;33:1369–73 doi:10.3174/ajnr.A2975 pmid:22576893

    Abstract/FREE Full Text
30. 30.↵
    1. Jander S,
    2. Turowski B,
    3. Kieseier BC, et al

    . Emerging tumefactive multiple sclerosis after switching therapy from NTZ to fingolimod. Mult Scler 2012;18:1650–52 doi:10.1177/1352458512463768 pmid:23100527

    CrossRefPubMed
31. 31.↵
    1. Tenembaum S,
    2. Chitnis T,
    3. Ness J, et al

    ; International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology 2007;68:S23–36 doi:10.1212/01.wnl.0000259404.51352.7f pmid:17438235

    CrossRefPubMed
32. 32.↵
    1. Khatri BO,
    2. Man S,
    3. Giovannoni G, et al

    . Effect of plasma exchange in accelerating NTZ clearance and restoring leukocyte function. Neurology 2009;72:402–09 doi:10.1212/01.wnl.0000341766.59028.9d pmid:19188571

    Abstract/FREE Full Text
33. 33.↵
    1. Pavlovic D,
    2. Patera AC,
    3. Nyberg F, et al

    ; Progressive Multifocal Leukeoncephalopathy Consortium. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 2015;8:255–73 doi:10.1177/1756285615602832 pmid:26600871

    CrossRefPubMed
34. 34.↵
    1. Kleinschmidt-Demasters BK,
    2. Miravalle A,
    3. Schowinsky J, et al

    . Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with NTZ. J Neuropathol Exp Neurol 2012;71:604–17 doi:10.1097/NEN.0b013e31825caf2c pmid:22710964

    CrossRefPubMed
35. 35.↵
    1. Salhofer-Polanyi S,
    2. Baumgartner A,
    3. Kraus J, et al

    . What to expect after NTZ cessation in a real-life setting. Acta Neurol Scand 2014;130:97–102 doi:10.1111/ane.12250 pmid:24720783

    CrossRefPubMedWeb of Science
36. 36.↵
    1. West TW,
    2. Cree BA

    . NTZ dosage suspension: are we helping or hurting? Ann Neurol 2010;68:395–99 doi:10.1002/ana.22163 pmid:20818793

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Sorensen PS,
    2. Koch-Henriksen N,
    3. Petersen T, et al

    . Recurrence or rebound of clinical relapses after discontinuation of NTZ therapy in highly active MS patients. J Neurol 2014;261:1170–77 doi:10.1007/s00415-014-7325-8 pmid:24728334

    CrossRefPubMedWeb of Science
38. 38.↵
    ADUHELM® Prescribing Information. https://biogencdn.com/us/aduhelm-pi.pdf. Accessed June 7, 2023
39. 39.↵
    1. Budd Haeberlein S,
    2. Aisen PS,
    3. Barkhof F, et al

    . Two randomized Phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 2022;9:197–210 doi:10.14283/jpad.2022.30 pmid:35542991

    CrossRefPubMed
40. 40.↵
    Food and Drug Administration. November 6, 2020 BLA 761178: Peripheral and Central Nervous System Drugs Advisory Committee Meeting. 2021. https://www.fda.gov/media/143505/download. Accessed July 12, 2023
41. 41.↵
    1. Cogswell PM,
    2. Barakos JA,
    3. Barkhof F, et al

    . Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol 2022;43:E19–35 doi:10.3174/ajnr.A7586 pmid:35953274

    Abstract/FREE Full Text
42. 42.↵
    1. Kim SH,
    2. Ahn JH,
    3. Yang H, et al

    . Cerebral amyloid angiopathy aggravates perivascular clearance impairment in an Alzheimer’s disease mouse model. Acta Neuropathol Commun 2020;8:181 doi:10.1186/s40478-020-01042-0 pmid:33153499

    CrossRefPubMed
43. 43.↵
    1. Greenberg SM,
    2. Bacskai BJ,
    3. Hernandez-Guillamon M, et al

    . Cerebral amyloid angiopathy and Alzheimer disease: one peptide, two pathways. Nat Rev Neurol 2020;16:30–42 doi:10.1038/s41582-019-0281-2 pmid:31827267

    CrossRefPubMed
44. 44.↵
    1. Zago W,
    2. Schroeter S,
    3. Guido T, et al

    . Vascular alterations in PDAPP mice after anti-Ab immunotherapy: implications for amyloid related imaging abnormalities. Alzheimers Dement 2013;9:S105–15 doi:10.1016/j.jalz.2012.11.010 pmid:23583235

    CrossRefPubMed
45. 45.↵
    1. Ostrowitzki S,
    2. Lasser RA,
    3. Dorflinger E, et al

    ; SCarlet RoAD Investigators. A Phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther 2017;9:95 doi:10.1186/s13195-017-0318-y pmid:29221491

    CrossRefPubMed
46. 46.↵
    1. Sperling RA,
    2. Jack CR,
    3. Black SE, et al

    . Amyloid related imaging abnormalities (ARIA) in amyloid modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367–85 doi:10.1016/j.jalz.2011.05.2351 pmid:21784348

    CrossRefPubMedWeb of Science
47. 47.↵
    1. Salloway S,
    2. Chalkias S,
    3. Barkhof F, et al

    . Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 2022;79:13–21 doi:10.1001/jamaneurol.2021.4161 pmid:34807243

    CrossRefPubMed
48. 48.↵
    1. Barakos J,
    2. Sperling R,
    3. Salloway S, et al

    . MR imaging features of amyloid related imaging abnormalities. AJNR Am J Neuroradiol 2013;34:1958–65 doi:10.3174/ajnr.A3500 pmid:23578674

    Abstract/FREE Full Text
49. 49.↵
    1. Sperling R,
    2. Salloway S,
    3. Brooks DJ, et al

    . Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012;11:241–49 doi:10.1016/S1474-4422(12)70015-7 pmid:22305802

    CrossRefPubMed
50. 50.↵
    1. Haller S,
    2. Haacke EM,
    3. Thurnher MM, et al

    . Susceptibility-weighted imaging: technical essentials and clinical neurologic applications. Radiology 2021;299:3–26 doi:10.1148/radiol.2021203071 pmid:33620291

    CrossRefPubMed
51. 51.↵
    1. van Dyck CH,
    2. Swanson CJ,
    3. Aisen P, et al

    . Lecanemab in early Alzheimer’s disease. N Engl J Med 2023;388:9–21 doi:10.1056/NEJMoa2212948 pmid:36449413

    CrossRefPubMed
52. 52.↵
    1. Burness CB,
    2. Deeks ED

    . Adalimumab. Drugs 2012;72:2385–95 doi:10.2165/11470250-000000000-00000 pmid:23231024

    CrossRefPubMed
53. 53.↵
    1. Borchers AT,
    2. Leibushor N,
    3. Cheema GS, et al

    . Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 2011;37:273–88 doi:10.1016/j.jaut.2011.08.002 pmid:21907543

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Magnano MD,
    2. Robinson WH,
    3. Genovese MC

    . Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004;22:S134–40 pmid:15552527

    PubMedWeb of Science
55. 55.↵
    1. Ramos-Casals M,
    2. Roberto-Perez A,
    3. Diaz-Lagares C, et al

    ; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9:188–93 doi:10.1016/j.autrev.2009.10.003 pmid:19854301

    CrossRefPubMed
56. 56.↵
    1. Bosch X,
    2. Saiz A,
    3. Ramos-Casals M

    ; BIOGEAS Study Group. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011;7:165–72 doi:10.1038/nrneurol.2011.1 pmid:21263460

    CrossRefPubMed
57. 57.↵
    1. Kemanetzoglou E,
    2. Andreadou E

    . CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep 2017;17:36 doi:10.1007/s11910-017-0742-1 pmid:28337644

    CrossRefPubMed